首页> 美国卫生研究院文献>Journal of the Canadian Association of Gastroenterology >A176 SOFOSBUVIR/VELPATASVIR-BASED REGIMENS ARE ASSOCIATED WITH EXCELLENT EFFICACY AND A SIGNIFICANT IMPROVEMENT OF PATIENTS-REPORTED OUTCOMES ACROSS PATIENT POPULATIONS: FROM NON-CIRRHOTICS TO COMPENSATED CIRRHOTICS TO DECOMPENSATED CIRRHOTICS

【2h】

A176 SOFOSBUVIR/VELPATASVIR-BASED REGIMENS ARE ASSOCIATED WITH EXCELLENT EFFICACY AND A SIGNIFICANT IMPROVEMENT OF PATIENTS-REPORTED OUTCOMES ACROSS PATIENT POPULATIONS: FROM NON-CIRRHOTICS TO COMPENSATED CIRRHOTICS TO DECOMPENSATED CIRRHOTICS

机译：基于A176的SOFOSBUVIR / VELPATASVIR方案具有出色的功效并且显着改善了患者在各种人群中报告的结果：从非数字疗法到代偿性电子病历再到对症下药

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

AimsOur aim was to assess the impact SOF/VEL±ribavirin (RBV) on patient-reported outcomes (PROs) in HCV patients with and without decompensated cirrhosis.

机译：目的我们的目的是评估SOF / VEL±利巴韦林（RBV）对有或没有失代偿性肝硬化的HCV患者的患者报告结局（PROs）的影响。

著录项

期刊名称 Journal of the Canadian Association of Gastroenterology
作者
Z M Younossi; M Stepanova; J Feld; S Zeuzem; M S Sulkowski; G R Foster; A Mangia; M Charlton; J O’Leary; M Curry; F Nader; L Henry; S Hunt;
展开▼
作者单位

展开▼
年(卷),期 2018(1),Suppl 1
年度 2018
页码 307–308
总页数 2
原文格式 PDF
正文语种
中图分类肠道病毒与肝炎病毒;肝及胆疾病;肠疾病;
关键词

相似文献

外文文献

1. Sofosbuvir/Velpatasvir (SOF/VEL)-Based Regimens are Associated with Excellent Efficacy and a Significant Improvement of Patients-Reported Outcomes (PROs) across Patient Populations: From Non-Cirrhotics to Compensated Cirrhotics to Decompensated Cirrhotics [J] . Younossi Zobair M., Stepanova Maria, Feld Jordan J., Hepatology: Official Journal of the American Association for the Study of Liver Diseases . 2016,第S1期

机译：基于Sofosbuvir / VelpataSvir（SOF / VEL）的方案与患者群体的患者报告的结果（专业人士）的优异疗效和显着改善有关：从非循环系统到补偿循环循环循环
2. Safety and Efficacy of the Fixed-Dose Combination Regimen of MK-3682/Grazoprevir/MK-8408 in Cirrhotic or Non-cirrhotic Patients with Chronic HCV GT1 Infection who Previously Failed a Direct-acting Antiviral Regimen (C-SURGE) [J] . Wyles David L., Wedemeyer Heiner, Reddy K. Rajender, Hepatology: Official Journal of the American Association for the Study of Liver Diseases . 2016,第S1期

机译：MK-3682 / GrazoPrevir / MK-8408在肝硬化或非肝硬化患者中的固定剂量组合方案的安全性和有效性慢性HCV GT1感染患者，慢性HCV GT1感染患者以前失败的直接作用抗病毒方案（C-SHORGE）
3. RESPONSE TO 16-WEEKS VERSUS 24-WEEKS DUAL THERAPY INCLUDING SOFOSBUVIR AND RIBAVIRIN, IN ALL CIRRHOTIC AND NON-CIRRHOTIC PATIENTS WITH HCV GENOTYPE- 3A INFECTION IN POPULATION OF KPKPAKISTAN [J] . Nizamud din, Jamalud din, Abid Shah, The Professional Medical Journal . 2018,第12期

机译：在所有KPK巴基斯坦人口的HCV基因型3A感染和非慢性感染的患者中，对16周对24周的双重治疗（包括索非布韦和利巴韦林）的反应
4. Modification of MELD Score by Including Serum Albumin to Improve Prediction of Mortality Outcome of Cirrhotic Patient Based on Thai Cirrhotic Patients [C] . Montri Duangkrut, Yaowadee Temtanapat, Piyawat Komolmit International Joint Conference on Computer Science and Software Engineering . 2014

机译：基于泰式肝硬化患者的血清白蛋白改变血清白蛋白的修改，提高肝硬化患者死亡率结果预测
5. Impact of Stent Type on Outcome of Cirrhotic Patients Treated with Transjugular Introhepatic Portosystemic Shunt [D] . Liu, Jiangtao. 2021

机译：支架类型对肝硬化血管内系统分流器治疗肝硬化患者结果的影响
6. An unfortunate failure: multifocal hepatocellular carcinoma in a non-cirrhotic patient with chronic hepatitis C treated with ledipasvir/sofosbuvir [O] . Megan Sue Soliman, Youssef Yousry Soliman, Qamar Ahmad, 2018

机译：不幸的失败：在非肝硬化的慢性丙型肝炎患者中使用利地帕韦/索非布韦治疗多灶性肝细胞癌
7. 03:27 PM Abstract No. 251 Post-embolization outcomes of splenic artery aneurysms in cirrhotic and non-cirrhotic patients [O] . S. Seedial, A. Gabr, S. Resnick, 2019

机译：03:27 PM摘要251号肝硬化和非肝硬化患者脾动脉瘤的栓塞后期栓塞突变症

A176 SOFOSBUVIR/VELPATASVIR-BASED REGIMENS ARE ASSOCIATED WITH EXCELLENT EFFICACY AND A SIGNIFICANT IMPROVEMENT OF PATIENTS-REPORTED OUTCOMES ACROSS PATIENT POPULATIONS: FROM NON-CIRRHOTICS TO COMPENSATED CIRRHOTICS TO DECOMPENSATED CIRRHOTICS

摘要

著录项

相似文献

相关主题

期刊订阅